Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 2
1991 1
1992 1
1993 1
1995 2
1997 3
1998 4
1999 4
2000 2
2001 2
2002 8
2003 3
2004 4
2005 7
2006 6
2007 4
2008 3
2009 2
2010 5
2011 2
2012 2
2013 1
2014 2
2015 4
2016 7
2017 5
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.
Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM. Sehn LH, et al. Among authors: klasa r. Blood. 2007 Mar 1;109(5):1857-61. doi: 10.1182/blood-2006-08-038257. Epub 2006 Nov 14. Blood. 2007. PMID: 17105812 Free article.
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group. Prince HM, et al. Lancet. 2017 Aug 5;390(10094):555-566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7. Lancet. 2017. PMID: 28600132
Limited-stage mantle-cell lymphoma.
Leitch HA, Gascoyne RD, Chhanabhai M, Voss NJ, Klasa R, Connors JM. Leitch HA, et al. Among authors: klasa r. Ann Oncol. 2003 Oct;14(10):1555-61. doi: 10.1093/annonc/mdg414. Ann Oncol. 2003. PMID: 14504058 Free article.
Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers.
Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB. Waterhouse DN, et al. Among authors: klasa r. Curr Cancer Drug Targets. 2006 Sep;6(6):455-89. doi: 10.2174/156800906778194586. Curr Cancer Drug Targets. 2006. PMID: 17017873 Review.
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.
van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A. van Oers MH, et al. Among authors: klasa r. Blood. 2006 Nov 15;108(10):3295-301. doi: 10.1182/blood-2006-05-021113. Epub 2006 Jul 27. Blood. 2006. PMID: 16873669 Free article. Clinical Trial.
78 results